Project Grant HT9425261E061
- Federal Grant Award Summary The Cleveland Clinic Foundation received a $700,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026 through April 30, 2030. The award funds research to decipher the role of the gut and tumor microbiome on ovarian cancer progression and resistance to chemotherapy. This hypothesis-driven research initiative aligns with the DHA's mission to transform healthcare for...
- Federal Grant Award Summary The Cleveland Clinic Foundation received a $750,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective April 1, 2026 through March 31, 2029. The project, titled "Leveraging Focal Adhesion Dependencies in CDH1-Deficient Lobular Breast Cancers," will be conducted at the organization's Cleveland, Ohio facility. This research initiative represents a hypothesis-driven...
- Federal Grant Award Summary The Cleveland Clinic Foundation received a $1.28 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. This four-year research award supports investigation of the biological mechanisms and therapeutic relevance of the SLC1A1 amino acid transporter in kidney cancer. The research will be conducted at the Cleveland Clinic Foundation's...
- Federal Project Grant Award Summary The Cleveland Clinic Foundation received a $559,992 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on September 30, 2025, with a completion date of September 29, 2028. The award supports bench-to-bedside development of superior CAR (Chimeric Antigen Receptor) T-cell therapy for leukemia, conducted at the organization's Cleveland, Ohio facility. This research initiative...
- This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,159,998.00 to The Cleveland Clinic Foundation, a non-profit academic medical center, to fund a research project titled "THERAPEUTIC IMMUNOSTIMULATORY MICROBES FOR TREATMENT OF OVARIAN CANCER". The award, which runs from September 1, 2024 to August 31, 2028, will support the Foundation's innovative biomedical research into developing...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Cleveland Clinic Foundation a $999,566 project grant effective November 1, 2025, through October 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). The award supports a three-year research initiative focused on magnetic resonance imaging-guided transcriptomic analysis of spinal cord neurodegeneration and demyelination in multiple sclerosis. This project represents a hypothesis-driven...
- This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding advanced biomedical research conducted by The Cleveland Clinic Foundation to investigate a novel mechanism for disrupting ovarian cancer progression. The total award amount is $780,357.00, with a performance period from May 1, 2025 to April 30, 2029. The research aims to elucidate the nuclear localization of the complement regulator CD55 as...
- The U.S. Department of Defense's Defense Health Agency (DHA) awarded a $2,602,024 Project Grant to The Cleveland Clinic Foundation under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, awarded on September 30, 2024, will fund research on the "Role of Stress in the Degradation of Intestinal IgA and Intestinal Health" over a 4-year period ending on September 29, 2028. As a prominent academic medical center, The Cleveland Clinic Foundation...
- The Defense Health Agency awarded a $640,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation, a non-profit academic medical center, to conduct research focused on "Evolutionary Experimentation Highlights Novel Therapeutic Vulnerabilities in Endometrial Cancer." The award duration is from September 1, 2024 to August 31, 2026. The Cleveland Clinic Foundation, which has extensive experience as both a prime...
- Federal Grant Award Summary The Cleveland Clinic Foundation received a $799,998 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 15, 2025, through September 14, 2028. The grant supports research focused on "Strategies Enhancing Spinal Plasticity to Promote Recovery from Spinal Cord Injury," with work to be performed at the organization's Cleveland, Ohio location. This research...
The Cleveland Clinic Foundation received a $700,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective May 1, 2026 through April 30, 2030. The award supports research investigating the role of the gut and tumor microbiome on ovarian cancer progression and resistance to chemotherapy. This research initiative aligns with the DHA's portfolio of hypothesis-driven biomedical research designed to transform healthcare for military service members and the American public through innovative medical solutions addressing critical health challenges. The research will be conducted at Cleveland Clinic's facilities in Cleveland, Ohio, with deliverables expected to include biomarker discovery, translational research findings, and scientific outputs advancing understanding of ovarian cancer mechanisms and therapeutic resistance. As a major academic medical center with demonstrated expertise in oncology and federally-funded research, Cleveland Clinic will execute the project through its Finance and Academic Affairs Fiscal Services Division, leveraging the organization's established capabilities in advanced research and clinical expertise to support this DHA-prioritized cancer research initiative.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $700.0k | 4/3/26 |